The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are April 9, 2020 | Issue Briefs Featured Will Medicare Prescription Drug Reform Legislation Make Insulin More Affordable?April 2, 2020 | Journal Article Pharmacy Benefit Managers: Practices, Controversies, and What Lies AheadMarch 26, 2019 | Issue Briefs Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare BeneficiariesJuly 1, 2019 | Journal Article Reducing Wasteful Spending in Employers’ Pharmacy Benefit PlansAugust 30, 2019 | Issue Briefs Prescription drugs accounted for 17 percent of total U.S. health care spending — or about $457 billion — in 2015. And that share is expected to rise over the next decade as drug costs outpace those of all other health care services. Policymakers need unbiased information and insight into what drives pharmaceutical prices and spending so they can develop feasible, effective policy solutions. Leave this field blank Our Experts Lovisa GustafssonVice President, Controlling Health Care Costs Media Mention read on: CNBCJanuary 14, 2019 Here's why many prescription drugs in the US cost so much—and it's not innovation or improvement FDA Actions on Drug Pricing A Timeline Explore Timeline The Latest in Prescription Drugs Narrow by: Author Anderson, ChloeAnderson, GerardAnderson, Kelly E.Baumgartner, Jesse C.Beutel, SophieBishop, ShawnBlumenthal, DavidBrooks-LaSure, ChiquitaCall, AdrienneColeman, AkeiisaCollins, Sara R.Conti, RenaCorr, BillDavis, KarenDoty, Michelle M.Duong, SophiaDusetzina, Stacie B.Ex, PatriciaFowler, ElizabethFrank, Richard G.Fry, CarrieGabel, Jon R.Ginsburg, Paul B.Glied, Sherry A.Green, Matthew Gunja, Munira Z.Gustafsson, LovisaGuyer, JocelynHorvath, JaneJha, Ashish K.Jost, Timothy S.Kang, So YeonKenyatta, KahaariKeohane, Laura M.Kesselheim, Aaron S.LaRosa, JoshLieberman, Steven M.Llamas, AlyssaMann, CindyMartin, KristiMcDonald, RuthMorgan, StevenMoulds, DonaldNuzum, RachelOran, RebeccaOsborn, RobinPanteli, DimitraPapanicolas, IreneParasrampuria, SonalPatel, KavitaPaxton, IsabelRamsay, ChristinaRiley, TrishRobinson, James C.Rodwin, Marc A.Rother, JohnSarnak, Dana O.Schneider, Eric C.Schoen, CathySeeley, ElizabethSeervai, ShanoorSen, Aditi P.Shah, ArnavSharp, JeremySquires, DavidStromberg, SamVela, LaurenWaxman, HenryWhitmore, HeidiWillink, AmberWoskie, Liana R.Wynne, BillyZhu, Benjamin Date Last 7 daysLast 30 daysLast 6 monthsPast yearOver a year agoOver 2 years agoOver 3 years agoOver 4 years agoOver 5 years ago Type Fund ReportsTo The PointIssue BriefsExplainerInfographicJournal ArticlePodcastOther Publication View By: Card View Card View List View Apply Leave this field blank Publication Reducing Wasteful Spending in Employers’ Pharmacy Benefit Plans August 30, 2019 By Lauren Vela To the Point Looking Ahead: Policy Options for Addressing High Drug Prices July 30, 2019 By Lovisa Gustafsson To the Point The Drug Pricing Debate Part II: The Many Acts of Congress July 30, 2019 By Billy Wynne, Josh LaRosa, Alyssa Llamas To the Point Why Is Progress Slowing on Diabetes Complications? July 5, 2019 By David Blumenthal, Shanoor Seervai Publication Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare Beneficiaries July 1, 2019 By Stacie B. Dusetzina To the Point States Are Using Drug Importation to Lower Costs and Provide Safe Access to Drugs June 27, 2019 By Jane Horvath To the Point How Drug Prices Are Negotiated in Germany June 13, 2019 By James C. Robinson, Patricia Ex, Dimitra Panteli To the Point Is Arbitration an Answer for High Drug Prices? May 3, 2019 By John Rother Publication Pharmacy Benefit Managers and Their Role in Drug Spending April 22, 2019 Publication Pharmacy Benefit Managers: Practices, Controversies, and What Lies Ahead March 26, 2019 By Elizabeth Seeley, Aaron S. Kesselheim To the Point Administration’s New Budget Proposals May Align with Bipartisan Congressional Action to Lower Drug Prices March 15, 2019 By Kristi Martin To the Point The Drug Pricing Debate: Sizing Up Recent Actions and What May Come Next March 7, 2019 By Billy Wynne, Josh LaRosa Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page Next › Last page Last »
